Satsuma Pharmaceuticals' Series A Round

Satsuma Pharmaceuticals raised a round of funding on December 21, 2016.

Satsuma Pharmaceuticals develops best-in-class therapies to address the unmet needs of migraine sufferers. The company's lead product candidate STS101 is a potential best-in-class therapy for migraine…

Articles about Satsuma Pharmaceuticals' Series A Round: